Search Results for "Human Growth Hormone And Ptsd"

15:51 EDT 24th March 2017 | BioPortfolio

Matching Channels

Growth hormone GH

Somatropin Hgh rDNA Pfizer

What is GENOTROPIN? GENOTROPIN (somatropin [rDNA origin] for injection) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference i...

EGF receptor Mab human rDNA Amgen

Luteinizing hormone LH and folliclestimulating hormone FSH

Follicle stimulating hormone FSH

Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART). FSH is used to induce development of multiple foll...

Matching News

OPKO weekly growth hormone jab fails in phase 3

US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adult growth ho...

FDA Grants Orphan Drug Designation to Genexine’s Investigational Growth Hormone Deficiency Drug

SEONGNAM, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, announced today that US FDA ...

Growth Hormone May Be Novel Therapy for Very Rare Bone Disease

Recombinant human growth hormone (rhGH) is a potential novel therapy for fibrogenesis imperfecta ossium (FIO), a very rare but disabling and ultimately fatal bone disease, a small study from India sug...

Medical News Today: Estrogen regulates the brain's fear response, protecting against PTSD

A new study examines how the sex hormone estrogen affects gene regulation in the brain, affecting the formation of fear memories and PTSD.

Growth hormone could be filed without further trials, says OPKO

OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co-dev...

OPKO Health GHD Candidate Fails Phase III Trial

OPKO Health said today that the long-acting human growth hormone candidate hGH-CTP, which is being developed in adults with growth hormone deficiency under a collaboration with Pfizer, has failed a Ph...

Growth Hormone Enhances Anaerobic Capacity

Growth hormone replacement therapy may help improve physical function and quality of life among GH-deficient adults. Clinical Endocrinology

Genexine gets Orphan designation for GHD therapy

Genexine Inc. (KOSDAQ:095700) said FDA granted Orphan Drug designation to the company's GX-H9 to treat growth hormone deficiency (GHD).The company expects full data this year from a Phase II trial of ...

Matching PubMed Articles

Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone.

To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of grow...

Oral delivery of human growth hormone: Preparation, characterization, and pharmacokinetics.

Daily subcutaneous injection of human growth hormone has been used for the treatment of growth hormone deficiency and growth failure but has led to poor patient compliance and renal toxicity. Thus, it...

Height Outcome of Recombinant Human Growth Hormone Treatment in Achondroplasia Children: A Meta-Analysis.

Although recombinant human growth hormone (rhGH) is not approved to treat short stature of achondroplasia (ACH), some studies suggested growth improvement during short-term rhGH treatment.

Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys.

TV-1106 is a recombinant human albumin genetically fused to growth hormone which is intended to reduce the frequency of injections for GH therapy users. We report the safety, tolerability, pharmacokin...

First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.

This study is a first time assessment of safety and tolerability, pharmacokinetics, and pharmacodynamics of RO5046013 in human, in comparison with unmodified rhIGF-I.

Search Whole site using Google

Quick Search
Advertisement Advertisement